Clinical Trials · NCT00082407
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 505
- Start date
- Nov 2003
- Locations
- 69 sites, 12 countries
- Primary endpoint
- Change in Glcosylated Hemoglobin (HbA1c)